Science
She Lobbied for Formaldehyde. Now She’s at E.P.A. Approving New Chemicals.
Formaldehyde, the chemical of choice for undertakers and embalmers, is also used in products like furniture and clothes. But it can also cause cancer and severe respiratory problems. So, in 2021, the Environmental Protection Agency began a new effort to regulate it.
The chemicals industry fought back with an intensity that astonished even seasoned agency officials. Its campaign was led by Lynn Dekleva, then a lobbyist at the American Chemistry Council, an industry group that spends millions of dollars on government lobbying.
Dr. Dekleva is now at the E.P.A. in a crucial job: She runs an office that has the authority to approve new chemicals for use. Earlier she spent 32 years at Dupont, the chemical maker, before joining the E.P.A. in the first Trump administration.
Her most recent employer, the chemicals lobbying group, has made reversing the Environmental Protection Agency’s course on formaldehyde a priority and is pushing to abolish a program under which the agency assess the risks of chemicals to human health. In recent weeks it has urged the agency to discard its work on formaldehyde entirely and start from scratch in assessing the risks.
The American Chemistry Council is also seeking to change the agency’s approval process for new chemicals and speed up E.P.A.’s safety reviews. That review process is a key part of Dr. Dekelva’s purview at the agency.
Another former chemistry council lobbyist, Nancy Beck, is back alongside Dr. Dekleva at the E.P.A. in a role regulating existing chemicals. The council’s president, Chris Jahn, told a Senate hearing shortly after the Trump inauguration that his group intended to tackle the “unnecessary regulation” of chemicals in the United States. “A healthy nation, a secure nation, an economically vibrant nation relies on chemistry,” he said.
It is not unusual or unlawful for industry groups to seek to influence public policy in the interest of their member companies. The A.C.C. estimates that products using formaldehyde support more than 1.5 million jobs in the United States.
What has been extraordinary, health and legal experts said, is the extent of the industry’s effort to block the E.P.A.’s scientific work on a chemical long acknowledged as a carcinogen, and how the architect of the effort was back at the agency as a regulator of chemicals. At the same time, the Trump administration has moved to sharply reduce the federal scientific work force.
“They already have a track record of ignoring the science,” said Tracey Woodruff, director of the Program on Reproductive Health and the Environment at the University of California, San Francisco. “Now, they’re in charge of government agencies that decide the rules.”
While leading the chemistry council’s fight to limit formaldehyde regulation, Dr. Dekleva called for investigations of federal officials for potential bias. The industry group used freedom of information laws to obtain emails of federal employees and criticized them in public statements for what they had written. It submitted dozens of industry-funded research papers to agencies that minimized the risks of formaldehyde.
The A.C.C. also sued both the E.P.A. and the National Academies, which advises the nation on scientific questions, accusing researchers of a lack of scientific integrity.
Allison Edwards, a chemistry council spokeswoman, said officials from the group had regularly met with E.P.A. staff members “to share critical science and to try and ensure an assessment of any chemistry is objective, employs rigorous scientific standards, and is reflective of real-world human exposure.” She said, “We’re asking to be one of many stakeholders at the table.”
Molly Vaseliou, a spokeswoman for the E.P.A., said the agency would continue to make sure it “ensures chemicals do not pose an unreasonable risk to human health or the environment.” At the same time, the agency would also work to approve “chemicals that are needed to power American innovation and competitiveness,” she said.
Formaldehyde’s cancer risk
Formaldehyde’s fumes can cause wheezing and a burning sensation in the eyes, especially when they accumulate indoors. That danger was apparent when formaldehyde in plywood used to build temporary trailer homes for victims of Hurricane Katrina sickened dozens of people.
And there are longer-term dangers, namely several types of cancers. The World Health Organization’s International Agency for Research on Cancer concluded in 2004 that the chemical is a human carcinogen, and the U.S. Department of Health listed it as a human carcinogen in 2011.
The chemical is restricted in the workplace, in certain composite wood products, and in pesticides. Yet efforts to strengthen overall regulations in the United States have stalled in the face of industry opposition.
President Biden, whose “cancer moonshot” program had made reducing cancer deaths a priority, revived in 2021 an E.P.A. assessment of the health effects of the chemical, and published a draft the following year. That effort, under the agency’s Integrated Risk Information System, was the first step toward regulating formaldehyde.
The chemistry council led a coalition of industry groups, including the Composite Panel Association and Kitchen Cabinet Manufacturers, arguing that formaldehyde had already been rigorously studied and that strict industry controls were in place.
In a half-dozen letters to the E.P.A., Dr. Dekleva, on behalf of a formaldehyde panel at the industry group, raised a list of complaints about the way the agency was carrying out its assessment.
She questioned research linking formaldehyde to leukemia, or cancer of the blood, and accused the agency of not relying on the best available science. There was a dose, she said, at which formaldehyde did not cause risk. There was also research, she said, that showed inhaled formaldehyde did not easily travel beyond the nose to cause harm to the body.
In light of these issues, Dr. Dekleva wrote, agency’s draft assessment was “flawed and unreliable without significant revision.”
To bolster its case, the industry group enlisted experts at consulting firms to submit opinions and studies to the E.P.A. minimizing formaldehyde’s risks. The firms included those previously commissioned by tobacco companies to help defend cigarettes.
The A.C.C. also submitted 41 peer-reviewed studies that it said refuted a link between formaldehyde and leukemia. A New York Times review found that the majority of the studies were funded by industry groups, including at least 11 from the Research Foundation for Health and Environmental Effects, an organization established by the American Chemistry Council.
David Michaels, an epidemiologist and professor at George Washington University School of Public Health and assistant secretary of labor under President Barack Obama, said the industry strategy was to create the appearance of disagreement among scientists.
While it’s true, he said, that inconsistencies can always exist in studies on humans, “there’s little disagreement among independent scientists that formaldehyde causes cancer.”
Scientists targeted
For more than 150 years, the National Academies has advised the U.S. government on science. In 2021, it was asked to weigh in on the E.P.A.’s work on formaldehyde.
It became a target of the American Chemistry Council.
The industry group used freedom of information laws to obtain internal emails of members and support staff of a panel assessing the E.P.A.’s formaldehyde review, and it accused one staff of showing “bias in favor of disputed research claiming formaldehyde causes leukemia.”
The staff member, a former Environmental Protection Agency scientist, had for example described as “wonderful” the news that Congress might try to replicate an influential Chinese study that had shown formaldehyde could cause leukemia.
Wendy E. Wagner, professor at the University of Texas School of Law and an expert on the use of science by environmental policymakers, said she did not see how the comment reflected bias. “After all, they don’t know what the results will be, do they?” she said. “I would expect all scientists to be enthusiastic about potential future research.”
Dr. Dekleva called for investigations at both the E.P.A. and the National Academies, and for the removal of potentially biased panel members and staff. That included scientists who had previously accepted federal research grants.
In July 2023, the industry group sued the E.P.A., as well as the National Academies, accusing researchers of a lack of scientific integrity. The chemistry council said that lack of integrity made the use of the National Academies research in regulating formaldehyde “arbitrary, capricious, and unlawful.”
“It was relentless, and beyond the pale,” said Maria Doa, a scientist at the E.P.A. for 30 years who is now senior director of chemicals policy at the Environmental Defense Fund. “They really ratcheted up their attacks on federal employees.”
The National Academies stood its ground, issuing a report the following month affirming the E.P.A.’s Integrated Risk Information System findings that formaldehyde is carcinogenic and increases leukemia risk.
Those conclusions are shared by other global health authorities.
Mary Schubauer-Berigan, the evidence-synthesis head at the World Health Organization’s Agency for Research on Cancer, said there was “sufficient evidence in humans” that formaldehyde causes leukemia as and nasopharynx cancer. Mikko Vaananen, a spokesman for the European Chemicals Agency, said that while some questions around specific links to leukemia remained unanswered, evidence was sufficient to classify formaldehyde as a carcinogen. Formaldehyde “cannot in principle be placed on the E.U. market,” he said.
In March 2024, a federal judge dismissed the chemistry council’s lawsuit. And early this year, near the end of the Biden administration, the E.P.A. issued a final risk determination, under the Toxic Substances Control Act: Formaldehyde “presents an unreasonable risk of injury to human health.”
Mary A. Fox, an expert in chemical risk assessment at the Johns Hopkins University Bloomberg School of Public Health and a member of a committee that reviewed the E.P.A.’s research on formaldehyde, said agency scientists had accurately reflected the uncertainties around the links between formaldehyde and leukemia. But they had documented many other streams of evidence that indicated that link, Dr. Fox said.
“It’s an inevitable progress of science, that as we learn more over time, we generally learn that health effects appear at lower concentrations than we had thought,” she said.
Following Mr. Trump’s re-election, the American Chemistry Council signed onto a letter from a range of industry groups calling for broad changes to policy, specifically citing formaldehyde. “We urge your administration to pause and reconsider” the E.P.A. findings on formaldehyde, the Dec. 5 letter said.
The E.P.A. “should go back to the scientific drawing board,” chemistry council said in January. The group was particularly concerned about the workplace limits the agency was suggesting, which it said ignored steps companies were already taking to protect workers, like the use of personal protective equipment.
The A.C.C. is also supporting a bill from Republican members of Congress that would end the Integrated Risk Information System.
Soon after, Trump transition officials said Dr. Dekleva would be returning to the E.P.A. to run a program assessing chemicals for approval. The chemistry council, which has long complained of a backlog, is pushing the agency to speed up approvals.
During the first Trump administration, agency whistle-blowers described in an inspector general’s investigation how they had faced “intense” pressure to eliminate the backlog, sometimes at the expense of safety. Shortly after the inauguration, the Trump administration fired the inspector-general who carried out the investigation.
On Jan. 20, the A.C.C. welcomed President Trump. “Americans want a stronger, more affordable country,” said Mr. Jahn, the group’s president. “America’s chemical manufacturers can help.”
Science
Not everyone is leaving California. A new commercial battery maker just landed in Sacramento
The lithium-ion batteries that supply much of today’s clean energy come with some infamous drawbacks, from fire risk to reliance on foreign mining.
Alternatives have been slow to get off the ground.
But California startup Peak Energy announced Wednesday it’s building a factory in Sacramento that will be the first in the U.S. to make sodium-ion battery packs at commercial scale.
Sodium-ion batteries have long held promise. They are made from cheap and abundant sodium ash deposits. The materials are less prone to overheating, so they don’t have the fire risk of lithium.
But they also store less energy per cubic inch. That means they have to be bigger and heavier, which makes them harder to fit into electric vehicles. So far, they’ve struggled to compete.
Peak Energy thinks it has an edge. The company focuses on storage systems big enough to power large data centers, factories and whole segments of the grid, where battery size matters less.
The company already delivers battery packs out of a small pilot project in San Francisco, but it has gotten $1.1 billion in preorders and now needs more space.
CEO and co-founder Landon Mossburg said its first products, each about the size of a shipping container, will begin rolling out in early 2027.
“We’re a 3-year-old company with over a billion in deposit-backed customer contracts, we’ve got grid deployment already, and all those products are exceeding expectations on the grid,” Mossburg said. “Those are really great signals.”
He founded Peak after working at Tesla and the now-folded Swedish battery company Northvolt. The battery cells, which make up the systems, will come from China.
Customers for Peak who have put down a deposit include independent power providers Jupiter Power, Energy Vault and RWE Americas, who are connecting utilities, and increasingly data centers, with batteries. Peak also works with utilities directly including one unnamed customer in California, and is “in fairly advanced discussions with two of the major hyperscalers,” Mossburg said.
Not everyone is so optimistic about the technology. Lithium-ion batteries are still cheaper, at least up front.
“Sodium-ion batteries attracted considerable interest when lithium-ion battery prices surged in 2022,” said Isshu Kikuma, an energy storage analyst at BloombergNEF. Since then, he noted, those prices have come down.
And as with lithium-ion battery chemistry, Asian manufacturers already have an edge.
“Sodium-ion cells are currently exclusively manufactured on a commercial scale within China,” said Evan Hartley, a research manager at the Benchmark Minerals consulting firm. Large producers such as BYD and CATL are spending enormous amounts to research and develop new products, he said.
Other U.S.-based sodium-ion startups have floundered of late. Natron Energy canceled plans to produce sodium-ion battery cells in North Carolina last year after funding difficulties. Bedrock Materials, which was making sodium-ion batteries for EVs, also closed up shop, citing a bet on a lithium supply shortage that hadn’t panned out.
But Peak Energy’s model is different, Mossburg said. Unlike Natron, it won’t be trying to make the batteries that go into their systems at first. They’ll import them, initially from China and later from other countries in Asia.
“While working at Tesla, I saw the advantage of focusing on a great end product that customers want before you try to bite off more of the scope,” Mossburg said.
Last month, Peak announced a partnership with General Motors to develop their own cells.
Once up and running, Peak Energy’s Sacramento factory will make three to four battery systems per day, each filled with almost 8,000 battery cells. One system can power hundreds of homes for four hours, Mossburg said. Customers will deploy tens or hundreds in a single project, “basically creating a power-plant sized battery” that can store power and supply the grid when energy is expensive, or directly serve facilities like data centers.
Although sodium-ion batteries cost more than lithium ones, Mossburg said Peak Energy’s battery systems still save customers money: The technology does not heat up like lithium, so it eliminates the need for expensive cooling technology.
“Because lithium-ion needs to actively cool, you’re basically paying to refrigerate your batteries or using energy to refrigerate your batteries, and we don’t need any of that stuff,” said Mossburg.
The upshot is a battery that’s cheaper, quieter, and safer.
“Safety is a major advantage for sodium-ion batteries,” Kikuma said.
That could matter in California, where battery opposition has surged after a fire at a Moss Landing energy storage facility drove the evacuation of 1,200 residents and contaminated nearby wetlands.
California has typically been a hub of battery research and development, not manufacturing. Mossburg said Peak Energy, which also has offices in Colorado, chose Sacramento for its proximity to a talented workforce, a growing energy storage market and the company’s engineering teams in Burlingame. He said the factory would create 239 new jobs.
The company hasn’t received any federal clean energy tax credits, but it got a $10.5-million tax credit from the state of California.
While sodium-ion is likely to remain a small fraction of the global battery market, Kikuma said stationary energy storage is one of the fastest growing applications for sodium-ion batteries.
Mossburg sees Peak as being ahead in this corner of the market.
“Everybody from CATL to GM have sort of validated now what we’re doing,” he said. “The market is trying to catch up.”
Science
What’s the deal with … coffee enemas?
It seems like nothing is off limits these days in L.A.’s most woo-woo wellness scenes. From ayahuasca circles and mail-order ketamine lozenges to off-label peptide injections, IV drips and longevity treatments, there’s a seemingly infinite number of ways to look and feel better that people will swear by in this town. Coffee enemas — mostly for digestive issues, but also for a host of other emotional and physiological conditions — is on that alleged miracle menu, and far more common than I even realized before I started writing this article.
“Oh, I have a friend who does that,” “Oh, my cousin swears by it,” I began hearing from people as soon as I started looking for interviewees.
Reddit contains hundreds of anecdotes — both enthusiastic and cautionary — about coffee enemas, which involve a person, often on their own, but sometimes with the assistance of an alternative health practitioner, filling a bag with coffee fluid, inserting a tube into their rectum, and slowly allowing the liquid to be absorbed. “Beware of coffee enemas,” reads the subject line of a post from a woman who did them regularly for a decade and reports feelings of exhaustion, spaciness and cravings when she tries to stop. “Caffeine in any form only (temporarily) masks and provides salve toward bigger, unaddressed issue(s),” she writes.
In response, another user — a person with Stage 4 ovarian cancer — jumps in to defend the practice. “Let’s respect what we are all doing, whether we agree or not,” they write. “I am doing conventional [treatment] in conjunction with alternative (I believe there is a place for both). I haven’t felt this good since my diagnosis. I feel light, have never felt jittery and chemotherapy had me so constipated I would cry.”
Over the last couple of decades, the interest in digestive health has grown exponentially, prompted by research on the gut-brain connection. According to a report by Grand View Research, the global gut health market was valued at $60.31 billion in 2025 and is projected to reach $114.83 billion by 2033. The growing number of people who are quietly (and often devoutly) doing coffee enemas is a part of this larger trend, which also includes fasting, cleanses, colonics, probiotics, food allergy and stool tests, and a number of other products and services intended to address everything from irregular or uncomfortable bowel movements to energy levels and mood. But what’s the deal with coffee enemas? And are they actually good for you? We talked to a wide range of people with an equally wide range of opinions.
Five enemas a day? Inside the controversial Gerson therapy
The pro-enema Reddit user coping with Stage 4 cancer posted that they do three coffee enemas daily. They discovered the practice through Gerson, an institute founded in 1978 to promote a treatment plan initially developed for tuberculosis, and later for cancer, migraines and other chronic conditions, by German American physician Dr. Max Gerson in the 1930s. If you visit the Gerson Institute website, the supplies for a coffee enema — organic therapy blend coffee ($9.75) and the complete enema bucket kit with catheter ($19) — are listed in its store. It has clinics in Tijuana, Budapest and Shangri-La, China.
Nicole Ferrer-Clement, executive director of the Gerson Institute, says the treatment plan, referred to as the Gerson therapy, has four parts, with five coffee enemas per day being the first part and an essential component of the protocol. The other parts include a vegetarian, fat-free diet, three juices (carrot, carrot and apple, and a green juice) and supplements. The idea behind the coffee enemas, she says, is that compounds (theobromine, theophylline, caffeine) in coffee stimulate the liver to produce more bile, which helps carry toxins out of the body through the digestive tract. Ferrer-Clement says this is important for cancer patients, whose livers may already be compromised while processing toxins released during treatment. Even though many people reach out to Gerson about coffee enemas for general health and wellness and constipation, she says that’s not generally something they recommend. The therapy remains controversial among mainstream oncologists, in part because there are few rigorous clinical studies evaluating its efficacy.
“We want research on [coffee enemas], we’re happy and open to do that, if someone is going to fund it,” Ferrer-Clement says, estimating the institute has treated thousands of patients over the years.
In addition to using coffee enemas to treat cancer, the majority of users online report turning to them for constipation. Many anecdotes are from people who tried more conventional medicine for digestive issues and, from a place of desperation, decided to look elsewhere for solutions. Others, like Chevanni Davids, a 33-year-old South African man living in Bali, use them to maintain a general sense of well-being. Davids — who grew up in South Africa, where culturally it’s common for grandmothers to administer enemas to children in rural areas — does a coffee enema twice per month. He was introduced to the practice of enemas with coffee by someone he describes as a Brazilian grandmother or elder. He swears by the practice, saying it’s kept his bowel movements regular and his emotional state at an equilibrium. Davids warns against doing them too frequently, however. “The addiction is a thing,” he says, “because it feels so, so good. After you do it once, you’re going to say, ‘I’m going to do that tomorrow.’”
A doctor’s take
Unsurprisingly, given that most people tend to find coffee enemas after reports of being failed by Western medicine, mainstream gastroenterology is not on board with this practice. “Coffee enemas are based on the ill-conceived idea that you’re washing toxins out of your colon, but your colon is not an organ that clears toxins like the liver,” says Dr. Barry Zamost, a gastroenterologist who was in private practice in Long Beach for more than 40 years. “This just flies in the face of all logic and physiology that any doctor has learned for 100 years.”
Zamost remembers first hearing of coffee enemas decades ago when Michael Landon, an actor best known for his roles on “Little House on the Prairie” and “Bonanza,” decided to reject chemotherapy in favor of alternative treatments following a pancreatic cancer diagnosis in 1991. Over his four decades in private practice, Zamost says he frequently saw patients with constipation who were frustrated and trying alternate methods, but that oral therapies such as laxatives, supplements and prescription medications remain the most safe and effective treatments.
A review of case reports from nine people who self-administered coffee enemas also concluded that there’s insufficient evidence to prove that the practice is helpful, and that it could be harmful, to the colon. Zamost says he thinks it’s unlikely for someone to cause themselves serious harm by doing coffee enemas, although it’s happened. He also says that in rare cases that enemas — not with coffee — are appropriate for patients who are severely constipated to provide temporary relief. But, generally, he doesn’t see any benefit to using coffee. As for why people report loving them? That’s easy enough to explain, he says. “Everybody feels better after a bowel movement. So if you gave yourself an enema that really made you feel like you were emptied, you’ll feel good. It doesn’t mean your health is better.”
The takeaway
Coffee enemas are likely not harmful when done in moderation, but we don’t have much more than anecdotal evidence at this point to indicate that they’re helpful either.
Science
Contributor: The crucial medical question that AI can’t ever answer
One of us got a call last spring from a longtime friend. The story was familiar: two doctors, an MRI, an online AI tool, a stack of articles — and one anxious question. “Everything tells me something different. The AI says I might need surgery. What should I do?”
We believe there’s one key response to anyone in this all-too-common conundrum: “What matters most to you?”
There was a long pause.
That pause is one of the most important moments in modern healthcare — and it is exactly the question artificial intelligence is unable to address.
In our careers as physicians and researchers, we have found, clearly and repeatedly, that for many common conditions the medical evidence does not point to a single “right” answer. The biology is often close. What determines the success of an outcome is whether the choice fits the person making it.
Some patients with back pain want the fastest possible return to physically demanding work, even if it means surgery. Others want to avoid an operation at almost any cost, even if recovery takes longer. The scan may look the same. The lives behind the scan are not.
That insight is becoming critically important as artificial intelligence moves deeper into everyday health decisions.
In our research on AI and clinical decision-making, we’ve studied what happens when systems are trained to optimize medical outcomes but are blind to human values. In plain English, today’s AI is very good at telling you what usually works for people like you with similar demographics and medical histories. It is far less capable of understanding what you are trying to protect, avoid or prioritize.
This matters because some of the most common and most expensive medical decisions are not purely biological. Should someone with low-risk prostate cancer choose surgery, radiation or careful monitoring? Should a person with atrial fibrillation undergo a procedure or manage the condition with medication? Should a patient with chronic knee or back pain operate now or try months of physical therapy to see whether surgery can be avoided?
In these situations, the medical differences between options are often small or uncertain. What makes the biggest difference is whether the treatment aligns with the patient’s goals: tolerance for risk, willingness to undergo recovery, ability to adhere to long-term therapy or simply what kind of life they want to live.
AI systems can calculate probabilities. They cannot determine what those probabilities mean to a particular person.
In some respects, artificial intelligence may know more medicine than any individual physician. It can synthesize millions of scientific papers, clinical studies and patient records in seconds. Yet it knows remarkably little about the person sitting across from it. AI does not know a patient’s goals, fears, obligations, tolerance for risk or personal definition of a good outcome. And because it knows little about either the patient or the physician, it knows even less about the conversation between them — the place where facts, values and trust come together to produce the right decision for a particular person.
A second patient story brought this home. A retired teacher was referred after an AI-based symptom checker flagged a heart rhythm abnormality and “favored” an invasive procedure. The patient arrived frightened, convinced there was one correct path. When we talked, it became clear that what mattered most was avoiding a long recovery and staying healthy enough to travel to see grandchildren.
Medication and monitoring — less dramatic, but well-supported by evidence — fit those goals better. The AI wasn’t wrong. It just didn’t know what mattered.
This blind spot is not trivial. Roughly a quarter of U.S. healthcare spending flows through decisions in which patient preferences meaningfully affect outcomes. When those preferences are ignored — by people or by algorithms — care becomes misaligned. That can mean unnecessary procedures, poor adherence, regret and rising costs without better health.
So what should consumers do when an app, portal or “smart” tool recommends a course of action?
Start with three questions.
First: “Best for whom?” If a tool says one option is best, ask whether it means best on average — or best for someone with your priorities.
Second: “What does this system not know about me?”
AI can see lab values and imaging results. It cannot see your job, your family responsibilities, your fears or what you are trying to get back to.
Third: “What happens if I wait or choose differently?”
Many important medical decisions are not emergencies. When options are close, taking time to reflect is often part of good care.
Artificial intelligence is becoming a powerful partner in medicine. It can help explain options, surface evidence and reduce confusion. But it should inform human decisions, not replace them.
AI may know more medicine than any physician.
It knows far less about any patient.
And it knows least about the conversation between them.
The most important variable in your healthcare is not in any algorithm. It is you.
James N. Weinstein is a surgeon and former chief executive of Dartmouth Health. He is a clinical professor at Northwestern University’s Kellogg School of Management and global head of Health Futures at Microsoft, which develops AI systems. Ogan Gurel is a physician and assistant professor at the University of Texas at Arlington, where he researches AI, causal inference and patient decision-making.
-
News20 minutes agoFormer Olympian pleads not guilty in reflecting pool vandalism charges
-
Los Angeles, Ca2 hours agoHeat advisory, beach hazards in effect as Southern California sizzles
-
Detroit, MI2 hours agoTeen on moped hit by car after cruising through stop sign in Detroit
-
San Francisco, CA2 hours agoFlight of fancy: San Francisco moves to build private luxury airport terminal
-
Dallas, TX2 hours agoDallas’ digital creator economy is booming. Burnout is too.
-
Miami, FL2 hours ago
I went to 2 famous Miami restaurants, a flashy steakhouse and a Cuban hot spot. Here’s how they compared.
-
Boston, MA2 hours agoPedestrian struck and killed in Roxbury – Boston News, Weather, Sports | WHDH 7News
-
Denver, CO2 hours agoSanta Fe Drive in Denver closed this weekend for pedestrian bridge construction